231 related articles for article (PubMed ID: 32757068)
21. Prognostic significance of
Kuyumcu S; Isik EG; Tiryaki TO; Has-Simsek D; Sanli Y; Buyukkaya F; Özkan ZG; Kalayoglu-Besisik S; Unal SN
Ann Nucl Med; 2021 Oct; 35(10):1147-1156. PubMed ID: 34185263
[TBL] [Abstract][Full Text] [Related]
22. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
23. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
24. Response assessment with the CXCR4-directed positron emission tomography tracer [
Herhaus P; Habringer S; Vag T; Steiger K; Slotta-Huspenina J; Gerngroß C; Wiestler B; Wester HJ; Schwaiger M; Keller U
EJNMMI Res; 2017 Dec; 7(1):51. PubMed ID: 28577295
[TBL] [Abstract][Full Text] [Related]
25.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
26. Comparison of [
Liu M; Chen X; Ding H; Shu Q; Zheng Y; Chen Y; Cai L
Mol Imaging Biol; 2024 Apr; ():. PubMed ID: 38627276
[TBL] [Abstract][Full Text] [Related]
27. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using
Weiberg D; Thackeray JT; Daum G; Sohns JM; Kropf S; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2018 Feb; 59(2):266-272. PubMed ID: 28775206
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.
Poschenrieder A; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2016 Dec; 6(1):70. PubMed ID: 27655427
[TBL] [Abstract][Full Text] [Related]
29. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
30. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.
Weich A; Werner RA; Buck AK; Hartrampf PE; Serfling SE; Scheurlen M; Wester HJ; Meining A; Kircher S; Higuchi T; Pomper MG; Rowe SP; Lapa C; Kircher M
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33805264
[TBL] [Abstract][Full Text] [Related]
31. Targeting CXCR4 with [
Lapa C; Kircher S; Schirbel A; Rosenwald A; Kropf S; Pelzer T; Walles T; Buck AK; Weber WA; Wester HJ; Herrmann K; Lückerath K
Oncotarget; 2017 Nov; 8(57):96732-96737. PubMed ID: 29228566
[TBL] [Abstract][Full Text] [Related]
32. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
Vag T; Steiger K; Rossmann A; Keller U; Noske A; Herhaus P; Ettl J; Niemeyer M; Wester HJ; Schwaiger M
EJNMMI Res; 2018 Sep; 8(1):90. PubMed ID: 30191351
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
34. [
Breun M; Monoranu CM; Kessler AF; Matthies C; Löhr M; Hagemann C; Schirbel A; Rowe SP; Pomper MG; Buck AK; Wester HJ; Ernestus RI; Lapa C
Front Oncol; 2019; 9():503. PubMed ID: 31245296
[TBL] [Abstract][Full Text] [Related]
35. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
36. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
37. Different extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [68Ga]Ga-pentixafor in patients with Waldenström macroglobulinemia and smoldering disease.
Pan Q; Cao X; Li J; Li F; Luo Y
Nucl Med Commun; 2024 May; ():. PubMed ID: 38745523
[TBL] [Abstract][Full Text] [Related]
38. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
39. Imaging Inflammation in Atherosclerosis with CXCR4-Directed [
Lu X; Calabretta R; Wadsak W; Haug AR; Mayerhöfer M; Raderer M; Zhang X; Li J; Hacker M; Li X
Life (Basel); 2022 Jul; 12(7):. PubMed ID: 35888127
[TBL] [Abstract][Full Text] [Related]
40. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
